Cytokinetics Names Jim Daly to Board of Directors
Cytokinetics (Nasdaq: CYTK) has appointed James M. Daly to its Board of Directors, effective August 19, 2025. Daly brings over 30 years of global biopharmaceutical leadership experience, particularly in commercialization.
Daly most recently served as Chief Commercial Officer at Incyte Corporation, where he led the Jakafi® launch. Previously, he spent 10 years at Amgen in senior leadership roles and 16 years at GlaxoSmithKline. He currently serves on the boards of Madrigal Pharmaceuticals, argenx SE, and Acadia Pharmaceuticals.
Cytokinetics (Nasdaq: CYTK) ha nominato James M. Daly nel suo Consiglio di Amministrazione, con decorrenza dal 19 agosto 2025. Daly vanta oltre 30 anni di esperienza nella leadership globale nel settore biofarmaceutico, con un particolare focus sulla commercializzazione.
Daly è stato recentemente Chief Commercial Officer presso Incyte Corporation, dove ha guidato il lancio di Jakafi®. In precedenza ha ricoperto ruoli dirigenziali senior per 10 anni in Amgen e per 16 anni in GlaxoSmithKline. Attualmente siede nei consigli di amministrazione di Madrigal Pharmaceuticals, argenx SE e Acadia Pharmaceuticals.
Cytokinetics (Nasdaq: CYTK) ha nombrado a James M. Daly en su Junta Directiva, con efecto desde el 19 de agosto de 2025. Daly aporta más de 30 años de experiencia en liderazgo global en biofarmacéuticas, especialmente en comercialización.
Daly fue recientemente Chief Commercial Officer en Incyte Corporation, donde dirigió el lanzamiento de Jakafi®. Anteriormente pasó 10 años en Amgen en puestos directivos y 16 años en GlaxoSmithKline. Actualmente forma parte de los consejos de Madrigal Pharmaceuticals, argenx SE y Acadia Pharmaceuticals.
Cytokinetics (Nasdaq: CYTK)는 2025년 8월 19일부로 James M. Daly를 이사회에 선임했다고 발표했습니다. Daly는 특히 상업화 분야에서 30년 이상의 글로벌 바이오제약 리더십 경험을 보유하고 있습니다.
Daly는 최근 Incyte Corporation에서 Chief Commercial Officer로 재직하며 Jakafi® 출시를 이끌었습니다. 이전에는 Amgen에서 10년간 고위 리더십 역할을, GlaxoSmithKline에서 16년을 근무했습니다. 현재는 Madrigal Pharmaceuticals, argenx SE, Acadia Pharmaceuticals의 이사회에서 활동하고 있습니다.
Cytokinetics (Nasdaq: CYTK) a nommé James M. Daly au sein de son conseil d'administration, à compter du 19 août 2025. Daly apporte plus de 30 ans d'expérience en direction au niveau mondial dans le secteur biopharmaceutique, notamment en commercialisation.
Daly a récemment occupé le poste de Chief Commercial Officer chez Incyte Corporation, où il a piloté le lancement de Jakafi®. Auparavant, il a passé 10 ans chez Amgen à des postes de direction et 16 ans chez GlaxoSmithKline. Il siège actuellement aux conseils d'administration de Madrigal Pharmaceuticals, argenx SE et Acadia Pharmaceuticals.
Cytokinetics (Nasdaq: CYTK) hat James M. Daly mit Wirkung zum 19. August 2025 in den Vorstand berufen. Daly bringt mehr als 30 Jahre Erfahrung in globaler Führungsposition in der Biopharma-Branche mit, insbesondere im Bereich Kommerzialisierung.
Daly war zuletzt Chief Commercial Officer bei Incyte Corporation und führte dort den Launch von Jakafi® an. Zuvor hatte er zehn Jahre lang Führungspositionen bei Amgen und 16 Jahre bei GlaxoSmithKline inne. Er ist derzeit Vorstandsmitglied bei Madrigal Pharmaceuticals, argenx SE und Acadia Pharmaceuticals.
- Addition of extensive commercial expertise to the board through an experienced industry veteran
- Strategic timing as company transitions towards becoming a commercial organization
- New director brings successful track record in drug launches and commercialization
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with particular expertise in commercialization to the Company’s Board of Directors.
“Jim has longstanding expertise leading commercial launches of innovative therapies, coupled with extensive Board experience guiding later-stage, global biopharma companies,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “We are pleased to welcome him to our Board and look forward to his contributions and oversight as our company advances toward becoming a fully integrated commercial organization.”
Most recently, Mr. Daly served as the Chief Commercial Officer at Incyte Corporation where he led the launch of Jakafi® (ruxolitinib) and oversaw development of the company’s global commercial capabilities. Previously, he spent 10 years at Amgen where he held multiple senior leadership positions, including Senior Vice President of North America Commercial Operations, and launched several successful medicines including Neulasta®, Xgeva®, Nplate® and Vectibix®. He began his career at GlaxoSmithKline, serving in escalating positions of seniority over his 16-year tenure with the company. He earned a B.S. in Pharmacy and an M.B.A. from the University at Buffalo, SUNY. Mr. Daly currently serves on the Boards of Madrigal Pharmaceuticals, argenx SE, and Acadia Pharmaceuticals.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology to advance a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), ulacamten, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
Who is Jim Daly and why did Cytokinetics (CYTK) appoint him to their board?
What is Jim Daly's experience in the pharmaceutical industry?
When did Jim Daly join Cytokinetics (CYTK) board of directors?
What other boards does Jim Daly serve on currently?
